PDE10 inhibitors. Claim 1: A compound of the formula (1) or a pharmaceutically acceptable salt thereof, wherein: A, together with X and the carbon atom to which it is attached, forms a C₆₋₁₀ aryl or heteroaryl 5 to 10 members, wherein said aryl or heteroaryl moiety is optionally substituted with up to 4 substituents, each independently selected from the group consisting of C₃₋₆ cycloalkyl,oxo, optionally substituted C₁₋₆ alkyl, optionally substituted C₁₋₆ alkoxy, hydroxy, cyano, halo, -NR⁵R⁶,-C (o) - No. 8309； r8310,-NH-C (O) R-C (O) -OR-C₁₋₆ alkyl-C₃₋₆ cycloalkyl,a. 4 to 6 members, phenyl and benzene； X represented by N or C； R1 represented by pitch c83218c83226；C₆₋₁₀ aryl or a 5-6 membered heterocyclic portion, wherein said alkyl, aryl or heterocyclic portion may be optionally substituted with up to 4 substituents, each independently selected from the group consisting of halogen, optionally substituted C₁₋₆ alkyl, optionally substituted C₁₋₆ alkoxy, hydroxy, cyano, -NR⁵R⁶,-C (o) - No. 8309； r8310,-NH-C (O) Ry -C (O) -ORR² and R³ are each independently represented by hydrogen, optionally substituted C₁₋₆ alkyl or optionally substituted C₁₋₆ alkoxy； R⁴,if present, it is optionally represented with up to 2 substituents, each independently selected from the group consisting of fluoro, hydroxy, optionally substituted C₁₋₆ alkyl or optionally substituted C₁₋₆ alkoxy, and； R⁵ and R⁶ are represented, each optionally and independently, by hydrogen or C₁₋₆ alkyl.Inhibidores de PDE10. Reivindicación 1: Un compuesto de la fórmula (1) o una sal de este aceptable desde el punto de vista farmacéutico, en donde: A, junto con X y el átomo de carbono al que está unido, forma un arilo C₆₋₁₀ o heteroarilo de 5 a 10 miembros, en donde dicha porción arilo o heteroarilo se sustituye opcionalmente con hasta 4 sustituyentes, cada uno seleccionado independientemente del grupo que consiste en cicloalquilo C₃₋₆, oxo, alquilo C₁₋₆ opcionalmente sustituido, alcoxi C₁₋₆ opcionalmente sustitui
